We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Principia Biopharma Inc | NASDAQ:PRNB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 100.05 | 99.65 | 100.05 | 0 | 01:00:00 |
From Jun 2019 to Jun 2024
By Mauro Orru
Sanofi SA said Friday that it intends to start a tender offer for the acquisition of U.S.-based biopharmaceutical company Principia Biopharma Inc.
The French pharmaceutical company said the offer to buy Principia in a deal that values the developer of a promising multiple sclerosis treatment at $3.68 billion is set to expire on Sept. 25.
Sanofi agreed to buy the U.S. company earlier in August.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
August 28, 2020 01:29 ET (05:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Principia Biopharma Chart |
1 Month Principia Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
